Axovant CEO David Hung Abruptly Exits, COO and Several Directors Also Resign
Axovant shares plunged after Hung abruptly resigned as CEO and also stepped down from his seat on the company board of directors. Source: BioSpace
3 Drugs That Could Make-or-Break AbbVie
A look at three drug approvals of vital importance to the company this year. Source: BioSpace
Sarepta Plunged After Adverse Event Forces Trial Halt in the UK
But the biotech swiftly indicated that it doesn’t expect the halt to last for long. Source: BioSpace
3 Biotech Gems to Stock Up on This Month
A look at a few bargains in today's choppy market. Source: BioSpace
FDA Officials Discuss Sentinel’s Challenges
The biggest challenge for the FDA’s 10-year-old Sentinel program for post-market safety monitoring of medical products is having to deal with a wide range of partners and data sources, according…
CEA Report: How Government Can Reduce Drug Prices, Increase Innovation in Pharma
The Council of Economic Advisers issued new recommendations for reducing drug pricing, including changes in government policies and regulations, such as moving Medicare Part B drug coverage into Part D.…
Budget Deal Boosts Discretionary Spending, But Unclear How Much FDA Will Benefit
The budget deal approved by lawmakers in the early hours on Friday raised caps on non-defense discretionary spending by $63 billion in fiscal 2018 and $68 billion in fiscal 2019,…
Wuhan Warned for Quality Controls, Adulterated Products
The FDA issued Wuhan Chinese Moxibustion Technology a warning letter for manufacturing adulterated products, and for quality and sanitation deficiencies. Source: Drug Industry Daily
Bipartisan Senate Bill Would Give NIH More Leeway to Explore Opioid Alternatives
A bipartisan group of members of the Senate Health Committee introduced a bill to increase National Institutes of Health research into non-opioid pain treatments. Source: Drug Industry Daily
Bioverativ Execs Snagged a Nice Payday After Sanofi Deal
It took more than 8 months and a series of sweetened offers, but Sanofi was able to close their $11.6B deal to buy Bioverativ without triggering an auction. Source: BioSpace
- Go to the previous page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- …
- 26
- Go to the next page